December 16, 2016 09:15 AM ESTUpdated 09:31 AM

Reeling Ophthotech eviscerates staff, laying off up to 135; Booming Regeneron adds more space

Shehla Shakoor

Managing Director

Four days after Ophthotech stock $OPHT cratered in the wake of a Phase III debacle for its wet, age-related macular degeneration drug Fovista, the biotech’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Reeling Ophthotech eviscerates staff, laying off up to 135; Booming Regeneron adds more space

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Are programs with compounded GLP-1s safe for your population?

Reel­ing Oph­thotech evis­cer­ates staff, lay­ing off up to 135; Boom­ing Re­gen­eron adds more space

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Reeling Ophthotech eviscerates staff, laying off up to 135; Booming Regeneron adds more space

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Are programs with compounded GLP-1s safe for your population?